Home Font Size: 1 2 3 Send to a Friend

Research Alliances

Research Alliances

Morphotek has proudly partnered with a number of world-class research institutions, including

										John Wayne Cancer Institute Research Collaboration, 2005 Morphotek & JWCI to develop antibodies to treat melanoma and lung cancer

										Johns Hopkins University Exclusive Technology License Agreement, 2000 Cornerstone patent that helped launch the company

										Ludwig Institute for Cancer Research Exclusive License Agreements, 2002 and 2004 Morphotek obtained exclusive rights to MORAb-003 and MORAb-004; two therapeutic monoclonal antibodies targeting antigens over-expressed in various cancers.

										National Cancer Institute Cooperative Research and Development Agreement, 2004 Exclusive License Agreement, 2005 Morphotek obtained exclusive rights to MORAb-009; a monoclonal antibody targeting a glycoprotein over-expressed in pancreatic and ovarian cancers and mesotheliomas.

										United States Army Medical Research Institute of Infectious Diseases "USAMRIID" Cooperative Research and Development Agreement, 2004 Morphotek to develop biomolecules that kill pathogenic microbes and fully human monoclonal antibodies that protect against the toxic effects of pathogenic antigens being developed for biowarfare

										United States Department of Defense Cooperative Research and Development Agreement, 2005 Morphotek to develop fully human, high-affinity, antibodies that can serve as biosensors for the early detection of pathogenic agents as well as be developed as drugs for the treatment of indivisuals at risk for exposure to biowarefare agents.
										Wistar Institute Research Collaboration Agreement, 2002 Morphotek applied its proprietary MORPHODOMA® technology to create optimized hybridoma cell lines for Wistar

©2005 Morphotek Inc. | 210 Welsh Pool Road | Exton, PA 19341 | (610) 423-6100 Privacy Policy | Site Map | Contact Us